Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 466

1.

First report of pulmonary large cell neuroendocrine carcinoma treated with stereotactic body radiation therapy.

McClelland S 3rd, Durm GA, Birdas TJ, Musto PM, Lautenschlaeger T.

Rep Pract Oncol Radiother. 2019 Nov-Dec;24(6):507-510. doi: 10.1016/j.rpor.2019.08.005. Epub 2019 Sep 2.

PMID:
31516396
2.

Infrared Spectroscopy of Polybenzimidazole in the Dry and Hydrate Forms: A Combined Experimental and Computational Study.

Musto P, La Manna P, Moon JD, Galizia M, Freeman BD.

ACS Omega. 2018 Sep 21;3(9):11592-11607. doi: 10.1021/acsomega.8b01699. eCollection 2018 Sep 30.

3.

Gastric Normal Adjacent Mucosa Versus Healthy and Cancer Tissues: Distinctive Transcriptomic Profiles and Biological Features.

Russi S, Calice G, Ruggieri V, Laurino S, La Rocca F, Amendola E, Lapadula C, Compare D, Nardone G, Musto P, De Felice M, Falco G, Zoppoli P.

Cancers (Basel). 2019 Aug 26;11(9). pii: E1248. doi: 10.3390/cancers11091248.

4.

A case of acute promyelocytic leukemia variant with derivative chromosome 3 der(3)t(3;8) associated with 8q partial gain.

Nozza F, Vona G, Trino S, D'Auria F, La Rocca F, Grieco V, Possidente L, De Luca L, Musto P.

Mol Cytogenet. 2019 Jul 5;12:32. doi: 10.1186/s13039-019-0445-1. eCollection 2019.

5.

Real world Italian experience of pomalidomide plus low-dose dexamethasone in the relapsed and refractory myeloma setting: extended follow-up of a retrospective multicenter study by the 'Rete Ematologica Pugliese E Basilicata'.

Mele G, Pastore D, Di Renzo N, Fragasso A, Guarini A, Mazza P, Musto P, Pavone V, Tarantini G, Curci P, Falcone AP, Mele A, Miccolis MR, Palazzo G, Palumbo G, Quinto AM, Reddiconto G, Rizzi R, Cascavilla N, Specchia G, Capalbo SF.

Leuk Lymphoma. 2019 Jul 9:1-4. doi: 10.1080/10428194.2019.1636989. [Epub ahead of print] No abstract available.

PMID:
31286780
6.

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.

Larocca A, Mina R, Offidani M, Liberati AM, Ledda A, Patriarca F, Evangelista A, Spada S, Benevolo G, Oddolo D, Innao V, Cangialosi C, Bernardini A, Musto P, Amico V, Fraticelli V, Paris L, Giuliani N, Falcone AP, Zambello R, De Paoli L, Romano A, Palumbo A, Montefusco V, Hajek R, Boccadoro M, Bringhen S.

Haematologica. 2019 Jun 27. pii: haematol.2019.220657. doi: 10.3324/haematol.2019.220657. [Epub ahead of print]

7.

Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs.

Montefusco V, Gay F, Spada S, De Paoli L, Di Raimondo F, Ribolla R, Musolino C, Patriarca F, Musto P, Galieni P, Ballanti S, Nozzoli C, Cascavilla N, Ben-Yehuda D, Nagler A, Hajek R, Offidani M, Liberati AM, Sonneveld P, Cavo M, Corradini P, Boccadoro M.

Haematologica. 2019 Jun 20. pii: haematol.2019.219139. doi: 10.3324/haematol.2019.219139. [Epub ahead of print]

8.

CD200 and prognosis in chronic lymphocytic leukemia: Conflicting results.

D'Arena G, Valvano L, Vitale C, Coscia M, Statuto T, Bellesi S, Lamorte D, Musto P, Laurenti L, D'Auria F.

Leuk Res. 2019 Aug;83:106169. doi: 10.1016/j.leukres.2019.106169. Epub 2019 Jun 11. No abstract available.

PMID:
31212087
9.

Deferasirox drives ROS-mediated differentiation and induces interferon-stimulated gene expression in human healthy haematopoietic stem/progenitor cells and in leukemia cells.

Tataranni T, Mazzoccoli C, Agriesti F, De Luca L, Laurenzana I, Simeon V, Ruggieri V, Pacelli C, Della Sala G, Musto P, Capitanio N, Piccoli C.

Stem Cell Res Ther. 2019 Jun 13;10(1):171. doi: 10.1186/s13287-019-1293-y.

10.

DNA methylation dynamic of bone marrow hematopoietic stem cells after allogeneic transplantation.

Trino S, Zoppoli P, Carella AM, Laurenzana I, Weisz A, Memoli D, Calice G, La Rocca F, Simeon V, Savino L, Del Vecchio L, Musto P, Caivano A, De Luca L.

Stem Cell Res Ther. 2019 May 20;10(1):138. doi: 10.1186/s13287-019-1245-6.

11.

Leg Type Primary Cutaneous Diffuse Large B-Cell Lymphoma.

D'Arena G, Galdo G, Lalinga V, Miraglia A, Pietrantuono G, Musto P, Vita G.

Indian J Hematol Blood Transfus. 2019 Apr;35(2):378-379. doi: 10.1007/s12288-018-1036-8. Epub 2018 Oct 29. No abstract available.

PMID:
30988585
12.

Morphology, molecular interactions and H2O diffusion in a poly(lactic-acid)/graphene composite: A vibrational spectroscopy study.

Musto P, La Manna P, Cimino F, Mensitieri G, Russo P.

Spectrochim Acta A Mol Biomol Spectrosc. 2019 Jul 5;218:40-50. doi: 10.1016/j.saa.2018.08.019. Epub 2018 Aug 13.

PMID:
30959345
13.

Francesco Lo Coco, a distinguished hematologist and a friend.

SIE, SIES and GIMEMA:, Corradini P, Musto P, Vignetti M.

Haematologica. 2019 Apr;104(4):855. doi: 10.3324/haematol.2019.222356. No abstract available.

14.

An update on biology, diagnosis and treatment of primary plasma cell leukemia.

Musto P, Statuto T, Valvano L, Grieco V, Nozza F, Vona G, Bochicchio GB, La Rocca F, D'Auria F.

Expert Rev Hematol. 2019 Apr;12(4):245-253. doi: 10.1080/17474086.2019.1598258. Epub 2019 Apr 12.

PMID:
30905220
15.

Features, reason for testing, and changes with time of 583 paroxysmal nocturnal hemoglobinuria clones from 529 patients: a multicenter Italian study.

Cannizzo E, Raia M, De Propris MS, Triolo A, Scarpati B, Marfia A, Stacchini A, Buccisano F, Lanza F, Regazzoli A, Michelutti A, Cesaro S, Conte CA, Vanelli L, Tedone E, Omedè P, Ciriello MM, Caporale R, Catinella V, Pantano G, De Rosa C, Lo Pardo C, Poletti G, Ulbar F, Pavanelli MC, Del Pup L, Ottaviano V, Santonocito AM, Bartocci C, Boscaro E, Arras M, Amodeo R, Mestice A, Oliva B, Ferrari L, Statuto T, D'Auria F, Pianezze G, Tanca D, Visconte F, Rubba F, Musto P, Geuna M, Gatti A, Brando B, Del Vecchio L.

Ann Hematol. 2019 May;98(5):1083-1093. doi: 10.1007/s00277-019-03644-8. Epub 2019 Mar 13.

PMID:
30868306
16.

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.

Fava C, Rege-Cambrin G, Dogliotti I, Cerrano M, Berchialla P, Dragani M, Rosti G, Castagnetti F, Gugliotta G, Martino B, Gambacorti-Passerini C, Abruzzese E, Elena C, Pregno P, Gozzini A, Capodanno I, Bergamaschi M, Crugnola M, Bocchia M, Galimberti S, Rapezzi D, Iurlo A, Cattaneo D, Latagliata R, Breccia M, Cedrone M, Santoro M, Annunziata M, Levato L, Stagno F, Cavazzini F, Sgherza N, Giai V, Luciano L, Russo S, Musto P, Caocci G, Sorà F, Iuliano F, Lunghi F, Specchia G, Pane F, Ferrero D, Baccarani M, Saglio G.

Haematologica. 2019 Aug;104(8):1589-1596. doi: 10.3324/haematol.2018.205054. Epub 2019 Feb 28.

17.

Thalidomide-induced psoriasis in a patient with multiple myeloma.

D'Arena G, Galdo G, Musto P.

Postgrad Med J. 2019 Mar;95(1121):171. doi: 10.1136/postgradmedj-2018-136317. Epub 2019 Feb 26. No abstract available.

PMID:
30808723
18.

An update on extracellular vesicles in multiple myeloma: a focus on their role in cell-to-cell cross-talk and as potential liquid biopsy biomarkers.

De Luca L, Laurenzana I, Trino S, Lamorte D, Caivano A, Musto P.

Expert Rev Mol Diagn. 2019 Mar;19(3):249-258. doi: 10.1080/14737159.2019.1583103. Epub 2019 Feb 26.

PMID:
30782029
19.

Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies.

Bringhen S, Mina R, Petrucci MT, Gaidano G, Ballanti S, Musto P, Offidani M, Spada S, Benevolo G, Ponticelli E, Galieni P, Cavo M, Di Toritto TC, Di Raimondo F, Montefusco V, Palumbo A, Boccadoro M, Larocca A.

Haematologica. 2019 Aug;104(8):1640-1647. doi: 10.3324/haematol.2018.208272. Epub 2019 Feb 7.

20.

Sorption Thermodynamics of CO₂, H₂O, and CH₃OH in a Glassy Polyetherimide: A Molecular Perspective.

Mensitieri G, Scherillo G, La Manna P, Musto P.

Membranes (Basel). 2019 Feb 1;9(2). pii: E23. doi: 10.3390/membranes9020023.

21.

Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations.

Girmenia C, Cavo M, Offidani M, Scaglione F, Corso A, Di Raimondo F, Musto P, Petrucci MT, Barosi G.

Blood Rev. 2019 Mar;34:84-94. doi: 10.1016/j.blre.2019.01.001. Epub 2019 Jan 9. Review.

PMID:
30683446
22.

Monoclonal B-cell lymphocytosis and prostate cancer: incidence and effects of radiotherapy.

D'Auria F, Valvano L, Rago L, Statuto T, Calice G, D'Arena G, Fusco V, Musto P.

J Investig Med. 2019 Apr;67(4):779-782. doi: 10.1136/jim-2018-000902. Epub 2019 Jan 11.

PMID:
30635362
23.

Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial.

Saltarella I, Morabito F, Giuliani N, Terragna C, Omedè P, Palumbo A, Bringhen S, De Paoli L, Martino E, Larocca A, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Dammacco F, Boccadoro M, Vacca A, Ria R.

J Hematol Oncol. 2019 Jan 9;12(1):4. doi: 10.1186/s13045-018-0691-4.

24.

Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations.

Girmenia C, Candoni A, Delia M, Latagliata R, Molteni A, Oliva EN, Palumbo GA, Poloni A, Salutari P, Santini V, Voso MT, Musto P.

Blood Rev. 2019 Mar;34:16-25. doi: 10.1016/j.blre.2018.10.002. Epub 2018 Oct 28. Review.

PMID:
30448050
25.

Evolution of monoclonal antibodies in multiple myeloma.

Musto P.

Lancet Oncol. 2018 Dec;19(12):1554-1555. doi: 10.1016/S1470-2045(18)30647-8. Epub 2018 Nov 12. No abstract available.

PMID:
30442500
26.

Future in the Past: Azorella glabra Wedd. as a Source of New Natural Compounds with Antiproliferative and Cytotoxic Activity on Multiple Myeloma Cells.

Lamorte D, Faraone I, Laurenzana I, Milella L, Trino S, De Luca L, Del Vecchio L, Armentano MF, Sinisgalli C, Chiummiento L, Russo D, Bisaccia F, Musto P, Caivano A.

Int J Mol Sci. 2018 Oct 26;19(11). pii: E3348. doi: 10.3390/ijms19113348.

27.

Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study).

Musto P, Simeon V, Cascavilla N, Falcone A, Petrucci MT, Cesini L, Di Raimondo F, Conticello C, Ria R, Catalano L, Salvatore D, Mastrullo L, Gagliardi A, Villani O, Pietrantuono G, D'Arena G, Mansueto G, Bringhen S, Genuardi M, Di Renzo N, Reddiconto G, Fragasso A, Caravita T, Scapicchio D, Marziano G, Boccadoro M, Mangiacavalli S, Corso A.

Ann Hematol. 2019 Feb;98(2):361-367. doi: 10.1007/s00277-018-3524-1. Epub 2018 Oct 23.

PMID:
30353388
28.

Functionalized Gold Nanoparticles as Biosensors for Monitoring Cellular Uptake and Localization in Normal and Tumor Prostatic Cells.

Pannico M, Calarco A, Peluso G, Musto P.

Biosensors (Basel). 2018 Oct 4;8(4). pii: E87. doi: 10.3390/bios8040087.

29.

Global methylation patterns in primary plasma cell leukemia.

Todoerti K, Calice G, Trino S, Simeon V, Lionetti M, Manzoni M, Fabris S, Barbieri M, Pompa A, Baldini L, Bollati V, Zoppoli P, Neri A, Musto P.

Leuk Res. 2018 Oct;73:95-102. doi: 10.1016/j.leukres.2018.09.007. Epub 2018 Sep 18.

PMID:
30257227
30.

Oxidative stress in chronic lymphocytic leukemia: still a matter of debate.

D'Arena G, Seneca E, Migliaccio I, De Feo V, Giudice A, La Rocca F, Capunzo M, Calapai G, Festa A, Caraglia M, Musto P, Iorio EL, Ruggieri V.

Leuk Lymphoma. 2019 Apr;60(4):867-875. doi: 10.1080/10428194.2018.1509317. Epub 2018 Sep 20.

PMID:
30234409
31.

Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis.

Bringhen S, Offidani M, Palmieri S, Pisani F, Rizzi R, Spada S, Evangelista A, Di Renzo N, Musto P, Marcatti M, Vallone R, Storti S, Bernardini A, Centurioni R, Aitini E, Palmas A, Annibali O, Angelucci E, Ferrando P, Baraldi A, Rocco S, Andriani A, Siniscalchi A, De Stefano V, Meneghini V, Palumbo A, Grammatico S, Boccadoro M, Larocca A.

Crit Rev Oncol Hematol. 2018 Oct;130:27-35. doi: 10.1016/j.critrevonc.2018.07.003. Epub 2018 Jul 18. Review.

PMID:
30196909
32.

Meningeal Involvement in Primary Plasma Cell Leukemia.

D'Arena G, Bitetti C, Daraia B, Pietrantuono G, Musto P.

Indian J Hematol Blood Transfus. 2018 Jul;34(3):556-557. doi: 10.1007/s12288-018-0943-z. Epub 2018 Mar 12. No abstract available.

33.

Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study.

Messa E, Gioia D, Masiera E, Castiglione A, Ceccarelli M, Salvi F, Danise P, Sanna A, Allione B, Balleari E, Poloni A, Cametti G, Ferrero D, Tassara R, Finelli C, Bonferroni M, Musto P, Saglio G, Levis A, Santini V.

Haematologica. 2019 Jan;104(1):e4-e8. doi: 10.3324/haematol.2017.183590. Epub 2018 Aug 3. No abstract available.

34.

European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias.

Gavriatopoulou M, Musto P, Caers J, Merlini G, Kastritis E, van de Donk N, Gay F, Hegenbart U, Hajek R, Zweegman S, Bruno B, Straka C, Dimopoulos MA, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M, Terpos E.

Leukemia. 2018 Sep;32(9):1883-1898. doi: 10.1038/s41375-018-0209-7. Epub 2018 Jul 23. Review.

35.

Extracellular Vesicles: A New Prospective in Crosstalk between Microenvironment and Stem Cells in Hematological Malignancies.

Laurenzana I, Lamorte D, Trino S, De Luca L, Ambrosino C, Zoppoli P, Ruggieri V, Del Vecchio L, Musto P, Caivano A, Falco G.

Stem Cells Int. 2018 May 27;2018:9863194. doi: 10.1155/2018/9863194. eCollection 2018. Review.

36.

Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.

Maurillo L, Buccisano F, Spagnoli A, Voso MT, Fianchi L, Papayannidis C, Gaidano GL, Breccia M, Musto P, De Bellis E, Del Principe MI, Lunghi M, Lessi F, Martinelli G, Venditti A.

Ann Hematol. 2018 Oct;97(10):1767-1774. doi: 10.1007/s00277-018-3374-x. Epub 2018 Jun 10.

PMID:
29947973
37.

Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.

Mina R, Petrucci MT, Corradini P, Spada S, Patriarca F, Cerrato C, De Paoli L, Pescosta N, Ria R, Malfitano A, Musto P, Baldini L, Guglielmelli T, Gamberi B, Mannina D, Benevolo G, Zambello R, Falcone AP, Palumbo A, Nagler A, Calafiore V, Hájek R, Spencer A, Boccadoro M, Bringhen S.

Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):533-540. doi: 10.1016/j.clml.2018.05.019. Epub 2018 May 28.

PMID:
29910180
38.

Monoclonal Antibodies and Multiple Myeloma: All in All It's Just Another Brick in the Wall?

Musto P.

Oncologist. 2018 May;23(5):511-515. doi: 10.1634/theoncologist.2018-0097. Epub 2018 Apr 26. No abstract available.

39.

Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis.

Cerrato C, Di Raimondo F, De Paoli L, Spada S, Patriarca F, Crippa C, Mina R, Guglielmelli T, Ben-Yehuda D, Oddolo D, Nozzoli C, Angelucci E, Cascavilla N, Rizzi R, Rocco S, Baldini L, Ponticelli E, Marcatti M, Cangialosi C, Caravita T, Benevolo G, Ria R, Nagler A, Musto P, Tacchetti P, Corradini P, Offidani M, Palumbo A, Petrucci MT, Boccadoro M, Gay F.

J Cancer Res Clin Oncol. 2018 Jul;144(7):1357-1366. doi: 10.1007/s00432-018-2641-5. Epub 2018 Apr 19.

PMID:
29675792
40.

CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia.

D'Arena G, Vitale C, Rossi G, Coscia M, Omedè P, D'Auria F, Statuto T, Valvano L, Ciolli S, Gilestro M, Molica S, Bellesi S, Topini G, Panichi V, Autore F, Innocenti I, Musto P, Deaglio S, Laurenti L, Del Vecchio L.

Hematol Oncol. 2018 Mar 30. doi: 10.1002/hon.2510. [Epub ahead of print]

PMID:
29602219
41.

Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' project.

Palandri F, Benevolo G, Iurlo A, Abruzzese E, Carella AM, Paoli C, Palumbo GA, Bonifacio M, Cilloni D, Andriani A, Guarini A, Turri D, Elli EM, Falcone A, Anaclerico B, Musto P, Di Renzo N, Tiribelli M, Zambello R, Spinosa C, Ricco A, Raucci L, Martino B, Annunziata M, Pascale S, Liberati AM, La Nasa G, Maffioli M, Breccia M, Pugliese N, Betti S, Giglio G, Cappuccio A, Reale L.

Qual Life Res. 2018 Jun;27(6):1545-1554. doi: 10.1007/s11136-018-1827-2. Epub 2018 Mar 8.

PMID:
29520559
42.

Pseudomembranous colitis in acute lymphoblastic leukaemia.

D'Arena G, Pietrantuono G, Musto P.

Postgrad Med J. 2018 Jun;94(1112):361. doi: 10.1136/postgradmedj-2018-135605. Epub 2018 Mar 2. No abstract available.

PMID:
29500180
43.

Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies.

D'Arena G, Vitale C, Coscia M, Festa A, Di Minno NMD, De Feo V, Caraglia M, Calapai G, Laurenti L, Musto P, Di Minno G, Fenoglio D.

J Immunol Res. 2017;2017:1832968. doi: 10.1155/2017/1832968. Epub 2017 Dec 21. Review.

44.

MicroRNAs as New Biomarkers for Diagnosis and Prognosis, and as Potential Therapeutic Targets in Acute Myeloid Leukemia.

Trino S, Lamorte D, Caivano A, Laurenzana I, Tagliaferri D, Falco G, Del Vecchio L, Musto P, De Luca L.

Int J Mol Sci. 2018 Feb 3;19(2). pii: E460. doi: 10.3390/ijms19020460. Review.

45.

Surface endoglin (CD105) expression on acute leukemia blast cells: an extensive flow cytometry study of 1002 patients.

Cosimato V, Scalia G, Raia M, Gentile L, Cerbone V, Visconte F, Statuto T, Valvano L, D'Auria F, Calice G, Graziano D, Musto P, Del Vecchio L.

Leuk Lymphoma. 2018 Sep;59(9):2242-2245. doi: 10.1080/10428194.2017.1416366. Epub 2018 Jan 15. No abstract available.

PMID:
29334284
46.

Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score.

Olivieri J, Attolico I, Nuccorini R, Pascale SP, Chiarucci M, Poiani M, Corradini P, Farina L, Gaidano G, Nassi L, Sica S, Piccirillo N, Pioltelli PE, Martino M, Moscato T, Pini M, Zallio F, Ciceri F, Marktel S, Mengarelli A, Musto P, Capria S, Merli F, Codeluppi K, Mele G, Lanza F, Specchia G, Pastore D, Milone G, Saraceni F, Di Nardo E, Perseghin P, Olivieri A.

Bone Marrow Transplant. 2018 Apr;53(4):461-473. doi: 10.1038/s41409-017-0051-y. Epub 2018 Jan 12.

PMID:
29330395
47.

Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.

Bringhen S, D'Agostino M, De Paoli L, Montefusco V, Liberati AM, Galieni P, Grammatico S, Muccio VE, Esma F, De Angelis C, Musto P, Ballanti S, Offidani M, Petrucci MT, Gaidano G, Corradini P, Palumbo A, Sonneveld P, Boccadoro M.

Leukemia. 2018 Apr;32(4):979-985. doi: 10.1038/leu.2017.327. Epub 2017 Nov 16.

PMID:
29263440
48.

Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma.

Pellegrini C, Broccoli A, Pulsoni A, Rigacci L, Patti C, Gini G, Mannina D, Tani M, Rusconi C, Romano A, Vanazzi A, Botto B, Santoro A, Hoaus S, Rigolin GM, Musto P, Mazza P, Molica S, Corradini P, Fama A, Gaudio F, Merli M, Ronconi F, Gritti G, Vallisa D, Tosi P, Liberati AM, Pinto A, Pavone V, Gherlinzoni F, Bianchi MP, Volpetti S, Trentin L, Goldaniga MC, Bonfichi M, De Renzo A, Schiavotto C, Spina M, Carella AM, Stefoni V, Argnani L, Zinzani PL.

Oncotarget. 2017 May 23;8(53):91703-91710. doi: 10.18632/oncotarget.18114. eCollection 2017 Oct 31.

49.

Unusual Hypergranular Myelomatous Plasma Cells.

D'Arena G, Musto P.

Indian J Hematol Blood Transfus. 2017 Dec;33(4):617-618. doi: 10.1007/s12288-017-0786-z. Epub 2017 Jan 30. No abstract available.

50.

Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).

Falantes J, Pleyer L, Thépot S, Almeida AM, Maurillo L, Martínez-Robles V, Stauder R, Itzykson R, Pinto R, Venditti A, Bargay J, Burgstaller S, Martínez MP, Seegers V, Cortesão E, Foncillas MÁ, Gardin C, Montesinos P, Musto P, Fenaux P, Greil R, Sanz MA, Ramos F; European ALMA + Investigators.

Leuk Lymphoma. 2018 May;59(5):1113-1120. doi: 10.1080/10428194.2017.1365854. Epub 2017 Aug 24.

PMID:
28838276

Supplemental Content

Support Center